Advanced
Genomic Sequencing Solutions
for Biopharma

Power drug discovery and precision medicine solutions with Sema4

With the rapid decline in next generation sequencing costs and the development of powerful tools to analyze genomic data, biopharma companies are now able to unlock invaluable, data-driven insights to advance precision medicine.

Sema4 offers industry-leading and information-driven genomic and analytics solutions to help accelerate the drug discovery, development, validation, and commercialization lifecycle. Sema4 employs the latest molecular, cytogenetic, and biochemical testing technologies in two CAP-accredited and CLIA-certified facilities where more than 250,000 tests are accessioned annually. Sema4 also uses cutting-edge NGS tests including whole exome sequencing (WES) and whole transcriptome sequencing (WTS) to deliver meaningful genomic insights at scale.

The assays’ unmatched sensitivity, accuracy, and coverage provide clinical-grade results appropriate for a multitude of pharma use cases including target biomarker discovery and clinical trial applications.

Icon
Accelerate biomarkers discovery and analysis
Icon
Access the broadest holistic view of a patient’s genome
Icon
Access bio-banked samples to aid retrospective sequencing and analysis using archival samples acquired throughout our network of collaborators
Icon
Combine genotypic and phenotypic data to provide holistic view of patients
Icon
Explore germline findings for cancer and non-cancer genes, as per ACMG guidelines, with relevance to comorbidities
Icon
Gain deep insights into novel fusions, splice variants & molecular pathways
Icon
Investigate driver mutational signature
Icon
Optimize prospective patient screening

Explore Sema4 solutions powering biopharma’s advanced sequencing needs

Learn more about how Merus is exploring new frontiers in drug development with Sema4

Strategic agreement to utilize Sema4’s advanced genomic testing to identify patients with tumors harboring neuregulin 1 gene (NRG1) fusions

In the constantly evolving drug development landscape, biopharma companies are increasingly in need of trusted partners at the vanguard of scientific progress who can provide holistic solutions to their most pressing problems. Researchers need to be empowered with revolutionary ways to identify novel compounds or re-use existing compounds, increase drug efficacy, reduce adverse reactions, and ultimately facilitate personalized therapies.

With the rapid decline in next generation sequencing costs and the development of powerful tools to analyze genomic data, biopharma companies are now able to unlock invaluable, data-driven insights to advance precision medicine. Contact us today to learn more about next generation sequencing solutions for biopharma.

Merus

Simple Icon

Accelerate biomarkers discovery and analysis

.

Simple Icon

Access the broadest holistic view of a patient’s genome

Simple Icon

Access bio-banked samples to aid retrospective sequencing and analysis using archival samples acquired throughout our network of collaborators

Simple Icon

Combine genotypic and phenotypic data to provide holistic view of patients

Simple Icon

Explore germline findings for cancer and non-cancer genes, as per ACMG guidelines, with relevance to comorbidities

Simple Icon

Gain deep insights into novel fusions, splice variants & molecular pathways

Simple Icon

Investigate driver mutational signature

Simple Icon

Investigate driver mutational signatureOptimize prospective patient screening

Therapeutic Area Deep-Dive

Oncology

Sema4 offers comprehensive oncology sequencing solutions for Biopharma through Sema4 Signal, a family of data-driven precision oncology solutions, to help facilitate and advance precision oncology care, from prevention to diagnosis and treatment. With a growing set of health systems running Sema4 Signal, it is an asset for clinical research teams wanting to find trial patients and generate data.

Learn more

Rare Disease

Using Sema4’s rich, longitudinal data and predictive modeling capabilities, biopharma companies can identify rare disease patients that may be under- or mis-diagnosed based on phenotypic characteristics more easily. When combined with Sema4’s genomic testing solutions, this approach allows these patients to be rapidly matched with relevant clinical trials or appropriate therapies.

Learn more

Start your Journey with Us

Kindly fill out the form below and we’ll schedule a time to discuss your needs.